Effect of tumour necrosis factor-alpha and interleukin-6 promoter polymorphisms on course of Crimean-Congo hemorrhagic fever in Turkish patients.
In this case-control study, we investigated whether IL-6 (-174G/C) and TNF-α (-308G/A) gene polymorphisms affect the clinical course and outcome of CCHF. Total 150 patients with CCHF and 170 controls were examined in this study. Genotyping of these polymorphisms were performed by PCR-RFLP methods. We found no statistically significant differences in genotype and allele frequencies of these polymorphisms between patients and controls [(χ2 = 1.31, p = 0.51 for TNF-α) and (χ2 = 2.61, p = 0.27 for IL-6)]. Either TNF-α AA or IL-6 CC genotypes in dead cases were not observed in this study. Frequency of heterozygous genotypes in both IL-6 (GC) and TNF-α (GA) was higher in dead patients than living patients. However, the difference was not statistically significant. A significant difference was found in AST levels and INR when compared to patients with CCHF who died and who survived [OR = 13.9 (95% CI = 1.79-107) for INR, p = 0.01] and [OR = 23.3 (95% CI = 3.62-149) for AST, p = 0.001], respectively. We did not find a significant association of IL-6 -174G/C and TNF-α -308G/A polymorphisms on the prognosis of CCHF and mortality in this study. We suggest that AST and INR may be important biomarkers for determining the risk of severity and death as a result of infection with Crimean-Congo hemorrhagic fever virus (CCHFV).